BRAF mutation may predict higher necessity of postoperative radioactive iodine ablation in papillary thyroid cancer

Annals of Surgical Treatment and Research

Volumn 87, Issue 4, 2014, Pages 174-179

  Han, Sang Ah ^a   Park, Won Seo ^b   Jang, Jae Hoon ^a   Min, Sun Young ^b   Ryu, Jung Kyu ^a   Song, Jeong Yoon ^a  

^a Kyung Hee University College of Medicine   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

Author keywords

Braf mutation; Papillary thyroid cancer; Radioactive iodine

Indexed keywords

EID: 84986921936     PISSN: 22886575     EISSN: 22886796     Source Type: Journal    
DOI: 10.4174/astr.2014.87.4.174     Document Type: Article

References (23)

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-7.
2. National Cancer Information Center [Internet]. Goyang: National Cancer Information Center; [cited 2011 Jun 20]. Available from: http://www.cancer.go.kr.
3. Previous version: SEER cancer statistics review, 1975-2009 (vintage 2009 populations) [Internet]. Bethesda: National Cancer Institute; [cited 2013 May]. Available from: http://seer.cancer.gov/csr/1975- 2009-pops09/.
4. Di Benedetto G, Fabozzi A, Rinaldi C, Rinaldi CR. BRAF test and cytological diag nosis with a single fine needle cytology sample. Acta Cytol 2013;57:337-40.
5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
6. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004;6:313-9.
7. Barollo S, Pennelli G, Vianello F, Watutantrige Fernando S, Negro I, Merante Boschin I, et al. BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F] fluoro-2-deoxy-D-glucose uptake ability. Eur J Endocrinol 2010;163:659-63.
8. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008;93:3943-9.
9. Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) 2012;91:274-86.
10. Ahn D, Park JS, Sohn JH, Kim JH, Park SK, Seo AN, et al. BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. Auris Nasus Larynx 2012;39:198-203.
11. Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg 2012;36:310-7.
12. Nam JK, Jung CK, Song BJ, Lim DJ, Chae BJ, Lee NS, et al. Is the BRAF(V600E) mutation useful as a predictor of pre operative risk in papillary thyroid cancer? Am J Surg 2012;203:436-41.
13. Lim JY, Hong SW, Lee YS, Kim BW, Park CS, Chang HS, et al. Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. Thyroid 2013;23:1423-30.
14. Min HS, Lee C, Jung KC. Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population. J Korean Med Sci 2013;28:534-41.
15. Namba H, Nakashima M, Hayashi T, Haya shida N, Maeda S, Rogounovitch TI, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393-7.
16. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012;118:1764-73.
17. Smith RA, Salajegheh A, Weinstein S, Nassiri M, Lam AK. Correlation between BRAF mutation and the clinico pathological parameters in papillary thyroid carcinoma with particular refe rence to follicular variant. Hum Pathol 2011;42: 500-6.
18. Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 2004;61:239-43.
19. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, et al. BRAF mutation in papillary thyroid carci noma in a Japanese population: its lack of correlation with high-risk clini copatho logical features and disease-free survival of patients. Endocr J 2009;56:89-97.
20. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, et al. BRAF (V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004;89:2414-20.
21. Cohen Y, Rosenbaum E, Clark DP, Zeiger MA, Umbricht CB, Tufano RP, et al. Mutational analysis of BRAF in fine needle aspi ration biopsies of the thyroid: a poten tial application for the pre operative assess ment of thyroid nodules. Clin Cancer Res 2004;10:2761-5.
22. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013;309:1493-501.
23. Cappola AR, Mandel SJ. Molecular testing in thyroid cancer: BRAF mutation status and mortality. JAMA 2013;309:1529-30.